Age: 88.0
Sex: U
Vaccine: COVID19
Symptoms: Antibody test, COVID-19, SARS-CoV-2 test
Clinical narrative: Covid-19 infection; This literature-non-study case was reported in a literature article and describes the occurrence of COVID-19 (Covid-19 infection) in an 88-year-old patient of an unknown gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Concurrent medical conditions included COPD, Obstructive sleep apnea syndrome and Diabetes mellitus.   On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced COVID-19 (Covid-19 infection) (seriousness criterion hospitalization). At the time of the report, COVID-19 (Covid-19 infection) outcome was unknown. Possible    DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Antibody test (0-1.39): 0.03 nl (normal) 0.03 nl, 0.03 nl (normal) 0.03 nl, 0.14 nl (normal) 0.14 nl and 0.14 nl (normal) 0.14 nl. On an unknown date, SARS-CoV-2 test: positive (Positive) Positive with cycle threshold of 13.6 and positive (Positive) Positive (cycle threshold-13.6).     For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter considered COVID-19 (Covid-19 infection) to be possibly related.    This case was considered as vaccination failure.   Patient presented with symptoms of Dyspnea and cough. After 2nd dose COVID-19 vaccination patient was hospitalization in 63 days. Lab test reports interpretation showed Acute infection. Peak supplemental Oxygen need was 2L/Min. Patient status at discharge was in Living condition.  Concomitant medications were not reported Treatment medications were not reported  This is a literature non study case concerning a 88-year-old, patient of unknown gender with medical history of BMI of 41, COPD, Obstructive sleep apnea syndrome and Diabetes mellitus,  who experienced the unexpected serious (by hospitalization and AESI) event of COVID 19 infection. The event occurred approximately 63 days after the second dose of Spikevax. The latency between doses or the start date of the first dose were not disclosed, so although the report states a vaccine breakthrough infection, lack of efficacy is not captured.   The rechallenge is not applicable. The medical history of BMI of 41, COPD, Obstructive sleep apnea syndrome and Diabetes mellitus are confounders for the event and the seriousness (hospitalization). The benefit-risk relationship of Spikevax is not affected by this report.   This case was linked to MOD-2021-362915, MOD-2021-362916.; Sender's Comments: This is a literature non study case concerning a 88-year-old, patient of unknown gender with medical history of BMI of 41, COPD, Obstructive sleep apnea syndrome and Diabetes mellitus,  who experienced the unexpected serious (by hospitalization and AESI) event of COVID 19 infection. The event occurred approximately 63 days after the second dose of Spikevax. The latency between doses or the start date of the first dose were not disclosed, so although the report states a vaccine breakthrough infection, lack of efficacy is not captured.   The rechallenge is not applicable. The medical history of BMI of 41, COPD, Obstructive sleep apnea syndrome and Diabetes mellitus are confounders for the event and the seriousness (hospitalization). The benefit-risk relationship of Spikevax is not affected by this report.